Becton Dickinson & Co. (NYSE:BDX) said today it won FDA 510(k) clearance for its line of Snowden-Pencer 3mm laparoscopic customizable surgical instruments.
The line of Snowden-Pencer instruments are designed for micro-laparoscopic surgery and are intended to function like 5mm instruments, the Franklin Lakes, N.J.-based company said. Jaw lengths on the devices are designed to mirror standard laparoscopic instruments to allow for a less invasive approach without loss of functionality.
“Minimally invasive micro-laparoscopic surgery is a steadily growing field resulting from patient demand for less invasive surgical options and scar reduction. This innovative new line of instruments enables providers to choose the best surgical option for their patients,” worldwide VP Jim Leitl said in a press release.
The newly cleared line offers 26 different jaw patterns, 2 lengths and 6 take-apart handles, the company said, to allow for maximized customizability.
In May, Becton Dickinson said it beat the consensus forecast with its fiscal 2nd-quarter earnings and said it plans to shift the business model for its U.S. medication management business.
The healthcare giant posted profits of $344 million, or $1.58 per share, on sales of $2.97 billion for the 3 months ended March 31, boosting the bottom line by 1.8% despite a -3.2% sales decline. BD said cited the divestiture of the controlling stake in its respiratory solutions business for the top-line reversal.
